NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Spear Bio

Spear Bio

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://spear.bio/

Last Round

Series A

Jul 29, 2024

Total Funding Raised

$45M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Spear Bio is a biotechnology company that develops ultrasensitive immunoassay technology for protein biomarker detection in research and clinical diagnostics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

immunoassayprotein biomarkerneurodegenerative diseasebiomarker detectionclinical diagnosticslaboratory automationprotein analysislife science toolsassay developmentCROclinical research organizationproteomicsbenchtop analyzerbiotech reagentsdrug discovery tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spear Bio Comps

Public and private peers based on sector, stage, and business model.

Spear Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Spear Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 29, 2024
SeedNov 29, 2023

Key People

Founding team and executive leadership

Feng Xuan

Co-Founder & CEO

Founding Team

Zidong Wang

Chief Operating Officer

Executive Team

Spear Bio Investors

Notable investors and investment history

Spear Bio investors
InvestorRounds
CDH InvestmentsSeries A, Seed
Maverick VenturesSeed, Series A
Yonjin CapitalSeries A
Yonghua CapitalSeed
Foresite CapitalSeries A
CDH InvestmentsSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2026

    Presented at AD/PD 2026 and launched new neurodegenerative assays.

  • Apr 9, 2026

    Launched new ultra-sensitive neurodegenerative assays at AD/PD 2026.

Spear Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Spear Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Spear Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range54
Year Founded2021
Last FundingJul 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.